Stonepine Capital Management LLC trimmed its position in shares of Exagen Inc. (NASDAQ:XGN – Free Report) by 6.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 358,697 shares of the company’s stock after selling 25,903 shares during the period. Exagen accounts for approximately 0.6% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 19th biggest position. Stonepine Capital Management LLC owned approximately 2.06% of Exagen worth $653,000 at the end of the most recent reporting period.
Separately, RTW Investments LP raised its stake in Exagen by 0.8% in the fourth quarter. RTW Investments LP now owns 1,504,602 shares of the company’s stock valued at $2,994,000 after buying an additional 12,170 shares during the period. Hedge funds and other institutional investors own 75.25% of the company’s stock.
Exagen Stock Performance
XGN opened at $3.09 on Tuesday. The company has a quick ratio of 4.32, a current ratio of 4.32 and a debt-to-equity ratio of 1.13. The stock has a market cap of $53.74 million, a price-to-earnings ratio of -2.83 and a beta of 1.32. Exagen Inc. has a 12-month low of $1.30 and a 12-month high of $3.71. The business has a 50 day moving average of $2.80 and a 200-day moving average of $2.10.
About Exagen
Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
See Also
- Five stocks we like better than Exagen
- Airline Stocks – Top Airline Stocks to Buy Now
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- Insider Trades May Not Tell You What You Think
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- What is an Earnings Surprise?
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.